Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Catinazzo Thomas, holds the title of Chief Financial Officer at Relay Therapeutics, Inc..
On 2026-11-18, the insider transacted 32,717 shares.The shares were transacted at a weighted average price of $16.51 per share, resulting in a total market-relevant value of $540K.
Catinazzo Thomas (Chief Financial Officer) sold $540K of $RLAY
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.